United Therapeutics UTHR Cash Flow Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $274.9M-14.7% | $364.3M+20.9% | $338.7M+9.6% | $309.5M+11.3% | $322.2M+5.1% | ||
| $22.6M+14.1% | $22.8M+15.7% | $21.9M+14.7% | $21.1M+12.8% | $19.8M+32.0% | ||
| $33.9M+6.6% | $39M+44.4% | $39.1M-6.2% | $37.8M-23.9% | $31.8M+24.2% | ||
| $25.9M— | —— | —— | —— | $0+100% | ||
| -$38.2M-189% | $52.5M— | —— | $57.3M— | $42.7M+50.9% | ||
| $40.1M+258% | $16.5M+42.2% | $17.5M+54.9% | $7.4M-49.7% | $11.2M+20.4% | ||
| -$12.7M-388% | $23.2M— | $31.2M-5.5% | $46.1M+78.7% | -$2.6M-237% | ||
| -$27M+79.9% | $98.2M+464% | -$67.2M-58.5% | $184.4M+35.2% | -$134.5M-78.1% | ||
| -$61.6M-1,062% | —— | —— | —— | -$5.3M— | ||
| $463.3M+0.5% | $346.2M+1.5% | $562.1M+49.0% | $191.7M-17.4% | $461.2M+22.5% | ||
| $100.8M+34.6% | $172.9M+99.4% | $210.5M+175% | $62.2M+37.9% | $74.9M+96.1% | ||
| $701.7M+1.4% | $520.3M+8.7% | $385.9M-5.4% | $1.81B+684% | $692.3M+30.8% | ||
| $1.31B— | $0— | $596M— | $1.27B— | $0-100% | ||
| $743.7M+552% | -$227.6M— | —— | -$299.9M— | -$164.7M-122% | ||
| $1.5B— | $0— | $1B— | $0— | $0-100% | ||
| $0-100% | —— | —— | $400M+300% | $100M0.0% | ||
| $68.3M+311% | $99M+285% | $40.2M+23.7% | $18.1M-65.3% | $16.6M-60.7% | ||
| $58.3M+281% | $600K+100% | $500K+25.0% | $200K+100% | $15.3M+34.2% | ||
| -$1.48B-1,483% | $0+100% | -$956M-1,391% | -$198.6M-314% | -$93.8M+91.2% | ||
| -$277.4M-237% | —— | -$253M-228% | -$306.8M-394% | $202.7M+363% | ||
| $1.9M-64.8% | $2M-72.2% | $1.9M-80.2% | $4.2M-61.1% | $5.4M-57.1% | ||
| $1.5M+200% | $51M-54.2% | $8.4M-89.1% | $253.4M+22.2% | $500K-89.4% | ||
| -$32M-680% | $33.6M+1,192% | $100K-98.2% | -$9.9M-280% | -$4.1M-139% | ||
| $5.7M-38.0% | —— | $5.7M-68.0% | $600K+50.0% | $9.2M+114% | ||
| $25M— | $25M-16.7% | $30M— | $0— | $0— | ||
| $269M-56.0% | $485.5M+1.6% | $182.5M-52.9% | $304.2M+54.8% | $611.7M+28.7% | ||
| $1.31B— | $0— | $596M— | $1.27B— | $0-100% | ||
| $5.6M+14.3% | —— | $4.3M+13.2% | —— | $4.9M+25.6% | ||
| $99.6M+111% | $24.1M— | $26M+356% | $19M— | $47.2M+100% | ||
| $1.5M+200% | $51M-54.2% | $8.4M-89.1% | $253.4M+22.2% | $500K-89.4% | ||
| $8.4M— | —— | $5.3M— | $0— | $0-100% | ||
| $362.5M-6.2% | $173.3M-31.9% | $351.6M+16.9% | $129.5M-30.8% | $386.3M+14.2% | ||
| $362.5M-6.2% | $173.3M-31.9% | $351.6M+16.9% | $129.5M-30.8% | $386.3M+14.2% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does United Therapeutics generate?
- United Therapeutics (UTHR) generated $1.6B in operating cash flow over the trailing twelve months.
- What is United Therapeutics's free cash flow?
- After $546.4M of capital expenditures, United Therapeutics's free cash flow was $1.0B over the trailing twelve months, down 9.9% year over year.
- Where does United Therapeutics's cash flow data come from?
- Every line is extracted from United Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
